Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ETCompany ParticipantsEli Kammerman - VP of Business ...

Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally ...

A federal jury ruled Friday that Masimo smartwatches infringed Apple patents, but Apple isn’t getting a big payday. Bloomberg Law reports that the company was only seeking the statutory minimum ...

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will ...

Q3 2024 Earnings Call Transcript November 5, 2024 Masimo Corporation beats earnings expectations. Reported EPS is $0.98, expectations were $0.84. Operator: Ladies and gentlemen, good afternoon, and ...

In this article, we are going to take a look at where Masimo Corporation (NASDAQ:MASI) stands against other most promising medical stocks. The healthcare sector depends on medical technology ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

A federal jury ruled Friday that Masimo smartwatches infringed Apple patents, but Apple isn’t getting a big payday. Bloomberg Law reports that the company was only seeking the statutory minimum of ...